Stratos Wealth Partners’s Zevra Therapeutics ZVRA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$3.8M Sell
408,000
-1,000
-0.2% -$9.01K 0.04% 389
2025
Q4
$3.66M Buy
409,000
+180,000
+79% +$1.7M 0.04% 399
2025
Q3
$2.18M Buy
229,000
+9,000
+4% +$90.3K 0.03% 510
2025
Q2
$1.94M Sell
220,000
-90,000
-29% -$730K 0.03% 502
2025
Q1
$2.32M Sell
310,000
-25,840
-8% -$205K 0.04% 410
2024
Q4
$2.8M Sell
335,840
-82,800
-20% -$707K 0.04% 390
2024
Q3
$2.91M Buy
418,640
+348,400
+496% +$2.36M 0.04% 371
2024
Q2
$344K Hold
70,240
0.01% 1043
2024
Q1
$407K Hold
70,240
0.01% 970
2023
Q4
$460K Buy
70,240
+40
+0.1% +$187 0.01% 901
2023
Q3
$338K Hold
70,200
0.01% 963
2023
Q2
$358K Hold
70,200
0.01% 884
2023
Q1
$386K Hold
70,200
0.01% 779
2022
Q4
$322K Hold
70,200
0.01% 865
2022
Q3
$438K Sell
70,200
-357
-0.5% -$2.02K 0.01% 739
2022
Q2
$315K Sell
70,557
-10
-0% -$46 0.01% 905
2022
Q1
$355K Sell
70,567
-1,290
-2% -$8.21K 0.01% 927
2021
Q4
$626K Buy
71,857
+900
+1% +$8.03K 0.01% 731
2021
Q3
$662K Buy
+70,957
New +$715K 0.02% 657
2018
Q4
Sell
-8
Closed -$1K 2557
2018
Q3
$1K Buy
+8
New +$625 ﹤0.01% 2900
2018
Q2
Sell
-8
Closed -$1K 2636
2018
Q1
$1K Hold
8
﹤0.01% 3049
2017
Q4
$0 Buy
+8
New +$483 ﹤0.01% 2838

Other funds holding ZVRA

Stratos Wealth Partners's ZVRA Position: Q1 2026 in Review

Stratos Wealth Partners reduced its Zevra Therapeutics (ZVRA) stake by 0.24% in Q1 2026, selling an estimated $9.01K and leaving 408,000 shares worth $3.8M. The position accounts for 0.04% of the portfolio, ranked #389.

Stratos Wealth Partners first reported a position in ZVRA in Q4 2017 and has held it in 22 quarters since. 148 funds tracked by Wall St. Rank hold ZVRA as of Q1 2026.

  • Stratos Wealth Partners held 408,000 shares of Zevra Therapeutics worth $3.8M as of Q1 2026.
  • Stratos Wealth Partners sold 1,000 Zevra Therapeutics shares in Q1 2026, an estimated $9.01K.
  • Zevra Therapeutics made up 0.04% of Stratos Wealth Partners's portfolio in Q1 2026, its #389 holding.
  • Stratos Wealth Partners first reported a position in Zevra Therapeutics in Q4 2017 and has held it in 22 quarters since.
  • 148 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.